Insight

Oct 31, 2024, 06:01

Nico Gagelmann: Bs Abs as bridging to BCMA CAR-T cell therapy for R/R multiple myeloma

Nico Gagelmann, Co- Chair of the The EBMT Trainee Committee, shared on X:

“Finally out!

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.”

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma

Authors: David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Patrick Born, Thomas Wiemers, Heike Weidner, Markus Kreuz, Tamara Schassberger, Jannik Kossmann, Marlene Mangold, Daniel Furst, Luise Fischer, Ronny Baber, Simone Heyn, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H. Metzeler, Marco Herlling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrike Kohl, Maik Friedrich, Andreas Boldt, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz.

Nico Gagelmann

Andreas Boldt Bispecific antibodies cancer Daniel Furst David Fandrei Enrica Bach Georg-Nikolaus Franke Heike Weidner Jannik Kossmann Klaus H Metzeler Kristin Reiche Luise Fischer Madlen Jentzsch Maik Friedrich Marco Herlling Markus Kreuz Marlene Mangold Maximilian Merz Michael Rade multiple myeloma Nico Gagelmann OncoDaily Oncology Patrick Born Ronny Baber Sabine Seiffert Sandra Hoffmann Simone Heyn Song Yau Wang Susanne Rieprecht Tamara Schassberger Thomas Wiemers Ulrike Köhl Uwe Platzbecker Vladan Vucinic

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology